Dupilumab: Phase III started

Sanofi and Regeneron began the double-blind, placebo-controlled, international Phase III LIBERTY AD CHRONOS trial to evaluate dupilumab given for 16 weeks in combination with topical corticosteroids in about 700 adults with moderate to severe atopic dermatitis. Patients will be monitored for a total of 52 weeks. ...